Trials / Completed
CompletedNCT00258635
Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test
A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Ragweed Allergoid With MPL® With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Patients Sensitized to Ragweed Pollen.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Allergy Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the immunological differences between three RagweedMATAMPL treatment arms compared to placebo with respect to immunoglobulin levels. In addition, the study will assess the reduced allergenicity of modified Ragweed Pollen contained in RagweedMATAMPL compared to unmodified native allergen using skin prick testing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RagweedMATAMPL |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2006-08-07
- Completion
- 2006-08-07
- First posted
- 2005-11-28
- Last updated
- 2021-06-11
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00258635. Inclusion in this directory is not an endorsement.